1. Home
  2. SKYE vs CHMI Comparison

SKYE vs CHMI Comparison

Compare SKYE & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • CHMI
  • Stock Information
  • Founded
  • SKYE 2012
  • CHMI 2012
  • Country
  • SKYE United States
  • CHMI United States
  • Employees
  • SKYE N/A
  • CHMI N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • CHMI Real Estate Investment Trusts
  • Sector
  • SKYE Health Care
  • CHMI Real Estate
  • Exchange
  • SKYE Nasdaq
  • CHMI Nasdaq
  • Market Cap
  • SKYE 80.7M
  • CHMI 92.0M
  • IPO Year
  • SKYE N/A
  • CHMI 2013
  • Fundamental
  • Price
  • SKYE $2.95
  • CHMI $3.32
  • Analyst Decision
  • SKYE Buy
  • CHMI Buy
  • Analyst Count
  • SKYE 6
  • CHMI 3
  • Target Price
  • SKYE $18.67
  • CHMI $5.00
  • AVG Volume (30 Days)
  • SKYE 169.1K
  • CHMI 315.5K
  • Earning Date
  • SKYE 02-13-2025
  • CHMI 03-06-2025
  • Dividend Yield
  • SKYE N/A
  • CHMI 18.05%
  • EPS Growth
  • SKYE N/A
  • CHMI N/A
  • EPS
  • SKYE N/A
  • CHMI N/A
  • Revenue
  • SKYE N/A
  • CHMI N/A
  • Revenue This Year
  • SKYE N/A
  • CHMI N/A
  • Revenue Next Year
  • SKYE N/A
  • CHMI $27.78
  • P/E Ratio
  • SKYE N/A
  • CHMI N/A
  • Revenue Growth
  • SKYE N/A
  • CHMI N/A
  • 52 Week Low
  • SKYE $2.31
  • CHMI $2.50
  • 52 Week High
  • SKYE $19.41
  • CHMI $3.99
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 47.80
  • CHMI 73.18
  • Support Level
  • SKYE $2.53
  • CHMI $3.07
  • Resistance Level
  • SKYE $4.25
  • CHMI $3.33
  • Average True Range (ATR)
  • SKYE 0.43
  • CHMI 0.09
  • MACD
  • SKYE 0.10
  • CHMI 0.04
  • Stochastic Oscillator
  • SKYE 28.84
  • CHMI 91.67

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

Share on Social Networks: